niacinamide has been researched along with Hypertension, Pulmonary in 15 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this paper was to examine the effects of nicotinamide (ND) and L-arginine (L-ARG) on pulmonary vascular and heart changes induced by pulmonary hypertension in rats in a gender-dependent way." | 7.96 | Protective effect of nicotinamide and L-arginine against monocrotaline-induced pulmonary hypertension in rats: gender dependence. ( Jankowski, Z; Kocić, I; Sztormowska-Achranowicz, K, 2020) |
| "We investigated the effects of the novel multikinase inhibitor sorafenib, which inhibits tyrosine kinases as well as serine/threonine kinases, in comparison to imatinib, a tyrosine kinase inhibitor, on hemodynamics, pulmonary and right ventricular (RV) remodeling, and downstream signaling in experimental pulmonary hypertension." | 7.74 | Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. ( Busch, AE; Dony, E; Ellinghaus, P; Ghofrani, HA; Grimminger, F; Klein, M; Milting, H; Nikolova, S; Pullamsetti, SS; Riedl, B; Savai, R; Schäfer, S; Schermuly, RT; Weissmann, N, 2008) |
| "Sorafenib treatment (daily gavage, 2." | 5.35 | Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. ( Desai, AA; Garcia, JG; Gomberg-Maitland, M; Husain, AN; Lang, RM; Liu, Y; Lussier, YA; Maitland, ML; Moreno-Vinasco, L; Ratain, MJ; Sam, L; Sammani, S; Singleton, PA, 2008) |
| "The purpose of this paper was to examine the effects of nicotinamide (ND) and L-arginine (L-ARG) on pulmonary vascular and heart changes induced by pulmonary hypertension in rats in a gender-dependent way." | 3.96 | Protective effect of nicotinamide and L-arginine against monocrotaline-induced pulmonary hypertension in rats: gender dependence. ( Jankowski, Z; Kocić, I; Sztormowska-Achranowicz, K, 2020) |
| "We investigated the effects of the novel multikinase inhibitor sorafenib, which inhibits tyrosine kinases as well as serine/threonine kinases, in comparison to imatinib, a tyrosine kinase inhibitor, on hemodynamics, pulmonary and right ventricular (RV) remodeling, and downstream signaling in experimental pulmonary hypertension." | 3.74 | Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. ( Busch, AE; Dony, E; Ellinghaus, P; Ghofrani, HA; Grimminger, F; Klein, M; Milting, H; Nikolova, S; Pullamsetti, SS; Riedl, B; Savai, R; Schäfer, S; Schermuly, RT; Weissmann, N, 2008) |
| " In order to assess the safety of sorafenib in PAH, patients with advanced but stable disease on parenteral prostanoids (with or without oral sildenafil) were initiated on treatment at the lowest active dosage administered to cancer patients: 200 mg daily." | 2.75 | A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. ( Archer, SL; Barst, RJ; Bond, L; Coslet, S; Gomberg-Maitland, M; Lacouture, ME; Maitland, ML; Perrino, TJ; Ratain, MJ; Sugeng, L, 2010) |
| "Sorafenib is a Raf kinase inhibitor and our biochemical and genomic evidence supported the potential involvement of the MAPK cascade system and TGFB3 in PH development and the response to therapy." | 2.46 | Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension. ( Garcia, JG; Moreno-Vinasco, L, 2010) |
| "Sorafenib is an inhibitor of multi-kinases including tyrosine and serine/threonine kinases." | 1.46 | Sorafenib as a potential strategy for refractory pulmonary arterial hypertension. ( Fukuda, K; Inami, T; Kataoka, M; Kimura, G; Satoh, T; Yoshino, H, 2017) |
| "Progression of pulmonary hypertension is associated with the activation of the NNMT-MNA pathway in rats and humans." | 1.43 | Activation of the nicotinamide N-methyltransferase (NNMT)-1-methylnicotinamide (MNA) pathway in pulmonary hypertension. ( Chlopicki, S; Fedorowicz, A; Jakubowski, A; Kopec, G; Kutryb-Zając, B; Mateuszuk, Ł; Skórka, T; Słomińska, E; Walczak, M; Zakrzewska, A; Łomnicka, M, 2016) |
| "Sorafenib treatment (daily gavage, 2." | 1.35 | Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. ( Desai, AA; Garcia, JG; Gomberg-Maitland, M; Husain, AN; Lang, RM; Liu, Y; Lussier, YA; Maitland, ML; Moreno-Vinasco, L; Ratain, MJ; Sam, L; Sammani, S; Singleton, PA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sztormowska-Achranowicz, K | 1 |
| Jankowski, Z | 1 |
| Kocić, I | 1 |
| Kimura, G | 1 |
| Kataoka, M | 2 |
| Inami, T | 1 |
| Fukuda, K | 2 |
| Yoshino, H | 1 |
| Satoh, T | 2 |
| Weatherald, J | 1 |
| Humbert, M | 2 |
| Guignabert, C | 2 |
| Montani, D | 2 |
| Leong, ZP | 1 |
| Hikasa, Y | 1 |
| Godinas, L | 1 |
| Seferian, A | 1 |
| Perros, F | 1 |
| Bergot, E | 1 |
| Sibille, Y | 1 |
| Mouraret, N | 1 |
| Houssaïni, A | 1 |
| Abid, S | 1 |
| Quarck, R | 1 |
| Marcos, E | 1 |
| Parpaleix, A | 1 |
| Gary-Bobo, G | 1 |
| Dubois-Randé, JL | 1 |
| Derumeaux, G | 1 |
| Boczkowski, J | 1 |
| Delcroix, M | 1 |
| Blasco, MA | 1 |
| Lipskaia, L | 1 |
| Amsellem, V | 1 |
| Adnot, S | 1 |
| Shaw, DE | 1 |
| Baig, F | 1 |
| Bruce, I | 1 |
| Chamoin, S | 1 |
| Collingwood, SP | 1 |
| Cross, S | 1 |
| Dayal, S | 1 |
| Drückes, P | 1 |
| Furet, P | 1 |
| Furminger, V | 1 |
| Haggart, D | 1 |
| Hussey, M | 1 |
| Konstantinova, I | 1 |
| Loren, JC | 1 |
| Molteni, V | 1 |
| Roberts, S | 1 |
| Reilly, J | 1 |
| Saunders, AM | 1 |
| Stringer, R | 1 |
| Sviridenko, L | 1 |
| Thomas, M | 1 |
| Thomson, CG | 1 |
| Tomlins, C | 1 |
| Wen, B | 1 |
| Yeh, V | 1 |
| Pearce, AC | 1 |
| Fedorowicz, A | 1 |
| Mateuszuk, Ł | 1 |
| Kopec, G | 1 |
| Skórka, T | 1 |
| Kutryb-Zając, B | 1 |
| Zakrzewska, A | 1 |
| Walczak, M | 1 |
| Jakubowski, A | 1 |
| Łomnicka, M | 1 |
| Słomińska, E | 1 |
| Chlopicki, S | 1 |
| Klein, M | 1 |
| Schermuly, RT | 2 |
| Ellinghaus, P | 1 |
| Milting, H | 1 |
| Riedl, B | 1 |
| Nikolova, S | 1 |
| Pullamsetti, SS | 2 |
| Weissmann, N | 2 |
| Dony, E | 1 |
| Savai, R | 1 |
| Ghofrani, HA | 2 |
| Grimminger, F | 2 |
| Busch, AE | 1 |
| Schäfer, S | 1 |
| Gomberg-Maitland, M | 2 |
| Maitland, ML | 2 |
| Barst, RJ | 1 |
| Sugeng, L | 1 |
| Coslet, S | 1 |
| Perrino, TJ | 1 |
| Bond, L | 1 |
| Lacouture, ME | 1 |
| Archer, SL | 1 |
| Ratain, MJ | 2 |
| Moreno-Vinasco, L | 2 |
| Garcia, JG | 2 |
| Abe, K | 1 |
| Toba, M | 1 |
| Alzoubi, A | 1 |
| Koubsky, K | 1 |
| Ito, M | 1 |
| Ota, H | 1 |
| Gairhe, S | 1 |
| Gerthoffer, WT | 1 |
| Fagan, KA | 1 |
| McMurtry, IF | 1 |
| Oka, M | 1 |
| Kojonazarov, B | 1 |
| Sydykov, A | 1 |
| Luitel, H | 1 |
| Dahal, BK | 1 |
| Kosanovic, D | 1 |
| Tian, X | 1 |
| Majewski, M | 1 |
| Baumann, C | 1 |
| Evans, S | 1 |
| Phillips, P | 1 |
| Fairman, D | 1 |
| Davie, N | 1 |
| Wayman, C | 1 |
| Kilty, I | 1 |
| Seeger, W | 1 |
| Tamura, Y | 1 |
| Ono, T | 1 |
| Sano, M | 1 |
| Desai, AA | 1 |
| Singleton, PA | 1 |
| Sammani, S | 1 |
| Sam, L | 1 |
| Liu, Y | 1 |
| Husain, AN | 1 |
| Lang, RM | 1 |
| Lussier, YA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Untersuchung Des Einflusses PAH-spezifischer Medikation Auf Die rechtsventrikuläre Funktion Bei Patienten Mit Pulmonaler Arterieller Hypertonie (PAH) Unter Basalen Bedingungen[NCT03362047] | Phase 2 | 30 participants (Anticipated) | Interventional | 2018-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for niacinamide and Hypertension, Pulmonary
| Article | Year |
|---|---|
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Topics: Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Endothelial Cells; ErbB Receptors; Familial Pr | 2013 |
Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension.
Topics: Animals; Benzenesulfonates; Calmodulin-Binding Proteins; Gene Expression; Gene Expression Profiling; | 2010 |
1 trial available for niacinamide and Hypertension, Pulmonary
| Article | Year |
|---|---|
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Benzenesulfonates; Diarrhea; Drug Discovery; Drug Dosage Calculations; Exanthema; Femal | 2010 |
12 other studies available for niacinamide and Hypertension, Pulmonary
| Article | Year |
|---|---|
Protective effect of nicotinamide and L-arginine against monocrotaline-induced pulmonary hypertension in rats: gender dependence.
Topics: Animals; Arginine; Female; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy, Right Ventricular | 2020 |
Sorafenib as a potential strategy for refractory pulmonary arterial hypertension.
Topics: Adolescent; Adult; Arterial Pressure; Dose-Response Relationship, Drug; Familial Primary Pulmonary H | 2017 |
Response to the article "Sorafenib as a potential strategy for refractory pulmonary arterial hypertension".
Topics: Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Niacinamide; Phenylurea Co | 2017 |
Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Autophagy; Disease Models, Animal; Dose-Respons | 2018 |
Role for telomerase in pulmonary hypertension.
Topics: Adult; Animals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Female; Humans; Hyperte | 2015 |
Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension.
Topics: Administration, Inhalation; Airway Remodeling; Animals; Cell Line; Cell Proliferation; Hypertension, | 2016 |
Activation of the nicotinamide N-methyltransferase (NNMT)-1-methylnicotinamide (MNA) pathway in pulmonary hypertension.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Animals; Case-Control Studies; Disease Models, Animal; Disease | 2016 |
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Topics: Animals; Benzamides; Benzenesulfonates; Blood Pressure; Disease Progression; Extracellular Signal-Re | 2008 |
Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.
Topics: Animals; Antihypertensive Agents; Benzamides; Benzenesulfonates; Blotting, Western; Calcium; Disease | 2011 |
Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.
Topics: Animals; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Hypertension, Pu | 2013 |
Favorable effect of sorafenib in a patient with neurofibromatosis-associated pulmonary hypertension.
Topics: Adult; Benzenesulfonates; Cardiac Catheterization; Exercise Test; Female; Humans; Hypertension, Pulm | 2012 |
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Complement C1q; Diseas | 2008 |